Zymeworks (ZYME)
(Delayed Data from NSDQ)
$15.61 USD
+0.95 (6.48%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.63 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.61 USD
+0.95 (6.48%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.63 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Zymeworks (ZYME) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zymeworks (ZYME) stock based on the movements in the options market lately.
Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season?
by Zacks Equity Research
Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Moving Average Crossover Alert: Zymeworks
by Zacks Equity Research
Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zymeworks Inc (ZYME) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to Decline
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zymeworks.
Red Hot Stocks Ahead of G20 Summit
by David Bartosiak
These Zacks Rank #1 (Strong Buy) stocks are breaking out while the rest of the market awaits the fate of the G20 Summit.
Will Zymeworks Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Zymeworks.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 6.35% and 2.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?